Requests that the FDA revoke its actions to approve the Abbreviate New Drug Application 216616, a generic version of Mifepristone, and modify the associated regimen (including the REMS) until the agency determines that it has complied with the various states’ water quality standards as compelled by the CWA

2 organizations filed 2 public comments on Requests that the FDA revoke its actions to approve the Abbreviate New Drug Application 216616, a generic version of Mifepristone, and modify the associated regimen (including the REMS) until the agency determines that it has complied with the various states’ water quality standards as compelled by the CWA, at the Food and Drug Administration.

Abstract

Open

Commenters (2)

• Center for Biological Diversity

  1 filing · confidence 97%
• Guttmacher Institutetrade assoc.

  1 filing · confidence 85%